News

In April 2009, Almirall signed a co-marketing agreement with Recordati, by virtue of which, Recordati grants Almirall marketing rights in Spain for Silodosin. Enrique Dominguez, general manager of

Nephoxil (ferric citrate) is a differentiated, iron-based phosphate binder for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end stage renal disease (ESRD). Nephoxil is free

With the introduction of ClearFoil X and ClearFoil Z, clear ultra-high barrier packaging options can now replace aluminum foil structures for those very demanding applications. The company claims

In the first model, ADX71943 reversed complete Freund adjuvant (CFA)- induced reductions in withdrawal thresholds in a dose-related manner, with a minimum effective oral dose of 10mg/kg. In

The company has partnered with Fujirebio Diagnostics in the development of the assay. The Architect HE4 assay has been approved for use in Europe, as well as in

As per terms of the agreement, Safecor Health is expected to provide Premier members a flexible and comprehensive menu of unit-dose and bar-coded repackaging services geared toward each

The new patent is based on the research by Alnylam scientists on systemic delivery of RNAi therapeutics as documented in Soutschek et al (Nature 432, 173-178 (11 November

The technology is based on a naturally occurring polysialic acid, which extends active life of a protein. PSA is biodegradable, non-immunogenic and non-toxic and is, therefore, expected to

As per the new agreement, Teva has extended its marketing and distribution rights to include the Nordic and Baltic regions, previously held by Active Biotech. Active Biotech is